A randomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney disease

Journal of Nuclear Cardiology

Volumn 19, Issue 2, 2012, Pages 319-329

  Ananthasubramaniam, Karthik ^a   Weiss, Robert ^b   McNutt, Bruce ^c   Klauke, Barbara ^c   Feaheny, Kathleen ^c   Bukofzer, Stan ^c  

^a HENRY FORD HOSPITAL   (United States)

^b Maine Research Associates   (United States)

^c ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

A2A adenosine receptor agonists; Chronic kidney disease; Regadenoson

Indexed keywords

PLACEBO; REGADENOSON;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; DYSPNEA; ECG ABNORMALITY; FEMALE; FLUSHING; GLOMERULUS FILTRATION RATE; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NECK PAIN; OXYGEN SATURATION; PARALLEL DESIGN; PHARMACOLOGIC STRESS TESTING; PR INTERVAL; PRIORITY JOURNAL; QRS COMPLEX; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; THORAX PAIN;

ADENOSINE A2 RECEPTOR ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; COMORBIDITY; CORONARY ARTERY DISEASE; DOUBLE-BLIND METHOD; DRUG TOLERANCE; DRUG TOXICITY; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PLACEBO EFFECT; PREVALENCE; PURINES; PYRAZOLES; RISK ASSESSMENT; RISK FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84863487137     PISSN: 10713581     EISSN: 15326551     Source Type: Journal    
DOI: 10.1007/s12350-011-9508-3     Document Type: Article

References (29)

1. Shryock JC, Belardinelli L. Adenosine and adenosine receptors in the cardiovascular system: Biochemistry, physiology, and pharmacology. Am J Cardiol 1997;79:2-10. (Pubitemid 27305162)
2. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. PharmacolRev 2001;53:527-52.
3. Cerqueira MD. The future of pharmacologic stress: Selective A2A adenosine receptor agonists. Am J Cardiol 2004;94:33D-40D.
4. Zablocki J, Palle V, Blackburn B, Elzein E, Nudelman G, Gothe S, et al. 2-substituted pi system derivatives of adenosine that are coronary vasodilators acting via the A2A adenosine receptor. Nucleosides Nucleotides Nucleic Acids 2001;20:343-60. (Pubitemid 32821797)
5. Gao Z, Li Z, Baker SP, Lasley RD, Meyer S, Elzein E, et al. Novel short-acting A2A adenosine receptor agonists for coronary vasodilation: Inverse relationship between affinity and duration of action of A2A agonists. J Pharmacol Exp Ther 2001;298:209-18. (Pubitemid 32574529)
6. Lexiscan (regadenoson injection) [prescribing information]. Deerfield, IL: Astellas Pharma US Inc. April 2011.
7. Buhr C, Gossl M, Erbel R, Eggebrecht H. Regadenoson in the detection of coronary artery disease. J Vasc Health Risk Manag 2008;4:337-40. (Pubitemid 351711962)
8. Hendel RC. Update on myocardial perfusion imaging: Role of regadenoson. Rep Med Imaging 2009;2:13-23.
9. Al Jaroudi W, Iskandrian AE. Regadenoson: A new myocardial stress agent. J Am Coll Cardiol 2009;54:1123-30.
10. Garnock-Jones KP, Curran MP. Regadenoson. Am J Cardiovasc Drugs 2010;10:65-71.
11. Thompson CA. FDA approves pharmacologic stress agent. Am J Health Syst Pharm 2008;65:890. (Pubitemid 351680033)
12. Gordi T, Blackburn B, Lieu H. Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function. J Clin Pharmacol 2007;47:825-33.
13. De Winter O, Van de Veire N, Gemmel F, Goethals I, De Sutter J. Myocardial perfusion imaging in the elderly: A review. Nucl Med Commun 2006;27:529-34. (Pubitemid 44309715)
14. Wetzels JF, Kiemeney LA, Swinkels DW, Willems HL, den Heijer M. Age- and gender-specific reference values of estimated GFR in Caucasians: The Nijmegen Biomedical Study. Kidney Int 2007;72: 632-7. (Pubitemid 47312796)
15. Stevens LA, Li S, Wang C, Huang C, Becker BN, Bomback AS, et al. Prevalence of CKD and comorbid illness in elderly patients in the United States: Results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2010;55:S23-33.
16. Leoncini G, Viazzi F, Rosei EA, Ambrosioni E, Costa FV, Leonetti G, et al. Chronic kidney disease in hypertension under specialist care: The I-DEMAND study. J Hypertens 2010;28:156-62.
17. Iskandrian AE, Bateman TM, Belardinelli L, Blackburn B, Cerqueira MD, Hendel RC, et al. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: Results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol 2007;14:645-58. (Pubitemid 47355078)
18. Cerqueira MD, Nguyen P, Staehr P, Underwood SR, Iskandrian AE, on behalf of the ADVANCE-MPI Trial Investigators. Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging. J Am Coll Cardiol Imaging 2008;1:307-16. (Pubitemid 351676842)
19. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247-54. (Pubitemid 46768608)
20. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70. (Pubitemid 29135798)
21. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med 2003;139:137-47.
22. Gordi T, Frohna P, Sun HL, Wolff A, Belardinelli L, Lieu H. A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers. Clin Pharmacokinet 2006;45:1201-12. (Pubitemid 44904823)
23. Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med 2005;353:2034-41. (Pubitemid 41609096)
24. Hendel RC, Bateman TM, Cerqueira MD, Iskandrian AE, Leppo JA, Blackburn B, et al. Initial clinical experience with regadenoson, a novel selective A2A agonist for pharmacologic stress single- photon emission computed tomography myocardial perfusion imaging. J Am Coll Cardiol 2005;46:2069-75. (Pubitemid 41713594)
25. Lieu HD, Shryock JC, von Mering GO, Gordi T, Blackburn B, Olmsted AW, et al. Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans. J Nucl Cardiol 2007;14:514-20. (Pubitemid 47163555)
26. Dhalla AK, Wong MY, Wang WQ, Biaggioni I, Belardinelli L. Tachycardia caused by A2A adenosine receptor agonists is mediated by direct sympathoexcitation in awake rats. J Pharmacol Exp Ther 2006;316:695-702. (Pubitemid 43130996)
27. Zhang Y, Zhang L, Abraham S, Apparaju S, Wu TC, Strong JM, et al. Assessment of the impact of renal impairment on systemic exposure of new molecular entities: Evaluation of recent new drug applications. Clin Pharmacol Ther 2009;85:305-11.
28. Cerqueira MD, Mahmarian JJ, Kinser C, Papatheofanis FJ, Segreti A. Frequency of aminophylline use to attenuate adverse reactions to regadenoson and adenosine. J Nucl Cardiol 2009;16:658. (abstract 10.01).
29. Johnson SG, Peters S. Advances in pharmacologic stress agents: Focus on regadenoson. J Nucl Med Technol 2010;38:163-71.